K C Balaji, MBBS, FRCS, MRCS, LRCP
Professor; Chair, Department Of Urology; Program Director, Advanced Urology Fellowship
Department:
Urology – Jacksonville
Business Phone:
(904) 244-7340
Business Email:
kethandapatti.balaji@jax.ufl.edu
About K C Balaji
K.C. Balaji, M.B.B.S., FRCS, MRCS, LRCP, is a University of Florida professor of urology and a board-certified urologist at UF Health Jacksonville. He also serves as chair of the UF Department of Urology – Jacksonville, as well as program director of the Advanced Urology Fellowship training program. Dr. Balaji received his medical degree from Madras Medical College in Park Town, India. He completed his medical residency in urology at University of Massachusetts Medical Center in Worcester, Massachusetts, as well as a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Balaji is widely known as a pioneer in the field of robotic surgery. He is highly regarded as an expert in managing advanced urological cancers of the prostate, bladder, kidney, testes and penis.
Additional Positions:
Professor
2018 – Current
·
University of Florida
Chair
2018 – Current
·
Department of Urology
Program Director
2018 – Current
·
Advanced Urology Fellowship
Accomplishments
Approved for Tenure
2022
·
University of Florida College of Medicine – Jacksonville
Teaching Profile
Courses Taught
2018
PAS5270 Urology
Board Certifications
-
UrologyAmerican Board of Urology
Clinical Profile
Specialties
- Urology
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-8057-2839
Publications
2023
Does care fragmentation in patients with bladder cancer lead to worse outcomes?
Urologic Oncology: Seminars and Original Investigations.
41(3):147.e7-147.e14
[DOI] 10.1016/j.urolonc.2022.10.028.
2023
Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.
American journal of clinical and experimental urology.
11(2):185-193
[PMID] 37168940.
2023
Genetic mutations in smoking-associated prostate cancer.
The Prostate.
83(13):1229-1237
[DOI] 10.1002/pros.24554.
[PMID] 37455402.
2023
Glomerular hyperfiltration is a predictor of adverse outcomes following major urologic oncology surgery.
International urology and nephrology.
55(2):229-239
[DOI] 10.1007/s11255-022-03400-4.
[PMID] 36318406.
2023
Magnetic resonance imaging radiomic features for recurrent prostate cancer following proton radiation therapy-A pilot study.
Urologic oncology.
41(3):145.e1-145.e5
[DOI] 10.1016/j.urolonc.2022.10.007.
[PMID] 36496342.
2023
MRI-based nomograms and radiomics in presurgical prediction of extraprostatic extension in prostate cancer: a systematic review.
Abdominal radiology (New York).
48(7):2379-2400
[DOI] 10.1007/s00261-023-03924-y.
[PMID] 37142824.
2023
Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men.
International urology and nephrology.
55(2):295-300
[DOI] 10.1007/s11255-022-03363-6.
[PMID] 36171482.
2023
Potential role for protein kinase D inhibitors in prostate cancer.
Journal of molecular medicine (Berlin, Germany).
101(4):341-349
[DOI] 10.1007/s00109-023-02298-4.
[PMID] 36843036.
2023
The geriatric nutritional risk index predicts complications after nephrectomy for renal cancer.
International braz j urol : official journal of the Brazilian Society of Urology.
49(1):97-109
[DOI] 10.1590/S1677-5538.IBJU.2022.0380.
[PMID] 36512458.
2023
The impact of socioeconomic status on the survival of men with early-onset prostate cancer.
American journal of clinical and experimental urology.
11(2):146-154
[PMID] 37168939.
2023
Urinary stone disease burden is increased in patients with cognitive impairment.
American journal of clinical and experimental urology.
11(3):249-257
[PMID] 37441445.
2022
3JC48-3 (methyl 4′-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth
Cancer Gene Therapy.
29(11):1550-1557
[DOI] 10.1038/s41417-022-00455-4.
2022
Complications after neoadjuvant chemotherapy and radical cystectomy for patients with bladder cancer: A propensity score matched analysis.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[DOI] 10.5489/cuaj.7952.
[PMID] 36473472.
2022
Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis.
Urologic oncology.
40(2):45-55
[DOI] 10.1016/j.urolonc.2021.11.008.
[PMID] 34895996.
2022
Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Abdominal radiology (New York).
47(12):4173-4185
[DOI] 10.1007/s00261-022-03669-0.
[PMID] 36112202.
2022
The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
The Journal of urology.
207(4):797-804
[DOI] 10.1097/JU.0000000000002342.
[PMID] 34854753.
2021
An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.
Journal of endourology.
35(4):409-416
[DOI] 10.1089/end.2020.0739.
[PMID] 32962442.
2021
Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.
Journal of robotic surgery.
15(3):321-333
[DOI] 10.1007/s11701-020-01174-4.
[PMID] 33222043.
2021
MRI and CT bladder segmentation from classical to deep learning based approaches: Current limitations and lessons.
Computers in biology and medicine.
134
[DOI] 10.1016/j.compbiomed.2021.104472.
[PMID] 34023696.
2021
Pathology grade influences competing mortality risks in elderly men with prostate cancer.
Urologic oncology.
39(8):493.e1-493.e7
[DOI] 10.1016/j.urolonc.2020.12.004.
[PMID] 33353870.
2021
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
Radiology.
298(1)
[DOI] 10.1148/radiol.2020202870.
[PMID] 33141006.
2020
A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy.
Urology.
144:21-27
[DOI] 10.1016/j.urology.2020.06.005.
[PMID] 32569659.
2020
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Urologic oncology.
38(11):826-834
[DOI] 10.1016/j.urolonc.2020.03.022.
[PMID] 32605736.
2020
Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia.
International urology and nephrology.
52(6):999-1008
[DOI] 10.1007/s11255-020-02408-y.
[PMID] 32065331.
2020
Re: Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-AnalysisA. Pilatz, K. Dimitropoulos, R. Veeratterapillay, Y. Yuan, M. I. Omar, S. MacLennan, T. Cai, F. Bruyère, R. Bartoletti, B. Köves, F. Wagenlehner, G. Bonkat and B. Pradere J Urol 2020; 204: 224-230.
The Journal of urology.
204(6):1349-1350
[DOI] 10.1097/JU.0000000000001332.
[PMID] 32830995.
2020
Symptomatic Pituitary Metastasis as Initial Manifestation of Renal Cell Carcinoma: Case Report and Review of Literature.
Case reports in endocrinology.
2020
[DOI] 10.1155/2020/8883864.
[PMID] 32908722.
2019
Protein kinase D1 induces G1-phase cell-cycle arrest independent of Checkpoint kinases by phosphorylating Cell Division Cycle Phosphatase 25.
The Prostate.
79(9):1053-1058
[DOI] 10.1002/pros.23807.
[PMID] 30958903.
2017
Beta-catenin represses protein kinase D1 gene expression by non-canonical pathway through MYC/MAX transcription complex in prostate cancer.
Oncotarget.
8(45):78811-78824
[DOI] 10.18632/oncotarget.20229.
[PMID] 29108267.
2016
Cell line modeling to study biomarker panel in prostate cancer.
The Prostate.
76(3):245-58
[DOI] 10.1002/pros.23116.
[PMID] 26764245.
2016
E-Cadherin Facilitates Protein Kinase D1 Activation and Subcellular Localization.
Journal of cellular physiology.
231(12):2741-8
[DOI] 10.1002/jcp.25382.
[PMID] 26991955.
2016
Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells.
Nanomedicine (London, England).
11(10):1207-22
[DOI] 10.2217/nnm-2015-0017.
[PMID] 27077564.
2016
Rapid bench to bed in management of metastatic prostate cancer.
Indian journal of urology : IJU : journal of the Urological Society of India.
32(4):255-256
[PMID] 27843205.
2015
Editorial comment.
The Journal of urology.
193(6):1916-7; discussion 1917
[DOI] 10.1016/j.juro.2014.12.107.
[PMID] 25770361.
2015
Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate.
The Prostate.
75(9):988-1000
[DOI] 10.1002/pros.22984.
[PMID] 25753731.
2015
The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.
The Prostate.
75(4):360-9
[DOI] 10.1002/pros.22922.
[PMID] 25408502.
2014
Autophagy: friend or foe for progression and treatment of urothelial carcinoma.
The Journal of urology.
191(6):1644-5
[DOI] 10.1016/j.juro.2014.03.082.
[PMID] 24647081.
2013
Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy.
Journal of endourology.
27(8):1046-50
[DOI] 10.1089/end.2012.0606.
[PMID] 23517015.
2010
Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer.
Cancer research.
70(5):2095-104
[DOI] 10.1158/0008-5472.CAN-09-4155.
[PMID] 20160036.
2010
Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail.
Cancer research.
70(20):7810-9
[DOI] 10.1158/0008-5472.CAN-09-4481.
[PMID] 20940406.
2010
Robotic partial cystectomy for bladder cancer: a single-institutional pilot study.
Journal of endourology.
24(2):223-7
[DOI] 10.1089/end.2009.0367.
[PMID] 20039797.
2009
Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells.
Oncogene.
28(49):4386-96
[DOI] 10.1038/onc.2009.291.
[PMID] 19767773.
2009
Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin.
Cancer research.
69(3):1117-24
[DOI] 10.1158/0008-5472.CAN-07-6270.
[PMID] 19141652.
2008
Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1.
Journal of cellular biochemistry.
104(1):82-95
[PMID] 17979146.
2008
Bryostatin 1 modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation.
Molecular cancer therapeutics.
7(9):2703-12
[DOI] 10.1158/1535-7163.MCT-08-0119.
[PMID] 18765827.
2008
Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells.
Biochemical and biophysical research communications.
373(4):618-23
[DOI] 10.1016/j.bbrc.2008.06.097.
[PMID] 18602367.
2007
Major urological oncological surgeries can be performed using minimally invasive robotic or laparoscopic methods with similar early perioperative outcomes compared to conventional open methods.
World journal of urology.
25(2):193-8
[PMID] 17171562.
2006
Comparative analysis of early perioperative outcomes following radical cystectomy by either the robotic or open method.
JSLS : Journal of the Society of Laparoendoscopic Surgeons.
10(2):145-50
[PMID] 16882409.
2006
Metallothioneins and resistance to cisplatin and radiation in prostate cancer.
Urology.
67(6):1341-7
[PMID] 16765200.
2006
N-cadherin switching occurs in high Gleason grade prostate cancer.
The Prostate.
66(2):193-9
[PMID] 16173043.
2006
Radical nephrectomy performed by open, laparoscopy with or without hand-assistance or robotic methods by the same surgeon produces comparable perioperative results.
International braz j urol : official journal of the Brazilian Society of Urology.
32(1):15-22
[PMID] 16519823.
2005
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Urologic oncology.
23(6):402-6
[PMID] 16301117.
2005
E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer.
Cancer research.
65(2):483-92
[PMID] 15695390.
2005
Feasibility of robotic radical nephrectomy–initial results of single-institution pilot study.
Urology.
65(6):1086-9
[PMID] 15913733.
2005
Robotic transperitoneal detrusor myotomy: description of a novel technique.
Journal of endourology.
19(4):476-9
[PMID] 15910260.
2005
Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.
Urologic oncology.
23(6):407-12
[PMID] 16301118.
2004
Feasibility of robot-assisted totally intracorporeal laparoscopic ileal conduit urinary diversion: initial results of a single institutional pilot study.
Urology.
63(1):51-5
[PMID] 14751347.
2004
Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model.
Urologic oncology.
22(4):313-20
[PMID] 15283889.
2003
Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer.
Biochemical and biophysical research communications.
310(3):1032-8
[PMID] 14550308.
2003
Protein kinase C mu is down-regulated in androgen-independent prostate cancer.
Biochemical and biophysical research communications.
307(2):254-60
[PMID] 12859948.
2002
Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data.
The Journal of urology.
167(1):57-60
[PMID] 11743275.
2001
Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium.
The Prostate.
48(4):265-73
[PMID] 11536306.
2000
Concordant prune belly syndrome in monozygotic twins.
Urology.
55(6)
[PMID] 10840120.
1999
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
The Journal of urology.
162(3 Pt 1):753-7
[PMID] 10458359.
1999
Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation.
The Journal of urology.
162(5):1603-6
[PMID] 10524877.
1997
Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer.
Urology.
50(6):1007-15
[PMID] 9426742.
1997
Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis.
The Prostate.
32(3):188-95
[PMID] 9254898.
1995
Laparoscopic diagnosis and management of transverse testicular ectopia.
Urology.
46(6):879-80
[PMID] 7502436.
Grants
Apr 2023
ACTIVE
A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants with Metastatic Castration-resistant Prostate Cancer
Role: Principal Investigator
Funding: FORTREA
via MACROGENICS
Sep 2022
ACTIVE
Establishment of an Inclusive Cancer Care Research Equity (iCCaRE) for Black Men Consortium
Role: Principal Investigator
Funding: MAYO CLINIC
via US DEPT OF DEFENSE
Jul 2022
ACTIVE
Protocol Title: A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetaxel Treatment (the Study)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP
via IMPACT THERAPEUTICS
May 2022
ACTIVE
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Na?ve or Received Incomplete BCG Treatment
Role: Principal Investigator
Funding: MEDPACE
via ENGENE
Aug 2021
ACTIVE
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via JANSSEN RESEARCH AND DEVELOPMENT
Feb 2021
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2020
ACTIVE
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN Registry)
Role: Principal Investigator
Funding: PROSTATE CANCER CLINICAL TRIALS CONS
Dec 2019
ACTIVE
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Sep 2019
ACTIVE
COMBINATORIAL INHIBITION OF MYC IN PROSTATE CANCER
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Feb 2019
ACTIVE
The collection of whole blood and other human bio-fluid specimens from subjects clinically diagnosed with cancer and/or other related disease.
Role: Principal Investigator
Funding: DISCOVERY LIFE SCIENCES
Jan 2019
ACTIVE
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP
via CONSTELLATION PHARMACEUTICALS
Education
Urologic Oncology Fellowship
1997-1999
·
Memorial Sloan-Kettering Cancer Center, New York, NY
Urology Residency
1993-1997
·
University of Massachusetts Medical Center, Worcester, MA
Medical Degree
1982-1986
·
Madras Medical College, Park Town, India
Contact Details
Phones:
- Business:
- (904) 244-7340
Emails:
- Business:
- kethandapatti.balaji@jax.ufl.edu
Addresses:
- Business Mailing:
-
653 W 8TH ST
JACKSONVILLE FL 32209